Limits...
Increased Secretion of Endogenous GH after Treatment with an Intranasal GH-releasing Peptide-2 Spray Does Not Promote Growth in Short Children with GH Deficiency.

Tanaka T, Hasegawa Y, Yokoya S, Nishi Y - Clin Pediatr Endocrinol (2014)

Bottom Line: Also no significant changes in blood IGF-I levels at baseline or after 48 wk of treatment were observed among the 3 groups.This study revealed that in patients with GHD, an increase in endogenous GH secretion as a result of treatment with GHRP-2 does not promote growth.In conclusion, it was demonstrated that growth cannot be promoted by a transient increase in endogenous GH secretion.

View Article: PubMed Central - PubMed

Affiliation: Tanaka Growth Clinic, Tokyo, Japan ; Department of Medical Specialties, National Center for Child Health and Development, Tokyo, Japan.

ABSTRACT
We investigated whether treatment with an intranasal GH-releasing peptide (GHRP)-2 spray, which acts as a potent GH secretagogue that stimulates endogenous GH secretion, promotes growth in patients with GH deficiency (GHD). This study involved 126 prepubertal short children (81 males, 45 females) with a height SD score of -2 SD or less, who had been diagnosed as having GHD based on GH stimulation tests, and in whom the serum GH concentrations increased up to 9 ng/ml after preliminary administration of an intranasal GHRP-2 spray. The subjects included in this study were divided into 3 groups by use of a double-blind method; that is 44 were placed into the placebo group (P group: 30 males, 14 females), 41 were placed into the GHRP-2 low dose group (L group: 25 males, 16 females), and 41 were placed into the GHRP-2 high dose group (H group: 26 males, 15 females). Those with a body wt of less than 20 kg were administered a placebo (P group), 50 μg of GHRP-2 (L group) or 100 μg of GHRP-2 (H group), and those with a body wt of 20 kg or more were administered a placebo (P group), 100 µg of GHRP-2 (L group) or 200 µg of GHRP-2 (H group) twice daily (morning and evening) for 48 continuous wk. Age and height SD scores at baseline were not significantly different among the three groups: 7.5 yr old and -2.26 SD in the P group, 7.3 yr old and -2.38 SD in the L group, and 7.5 yr old and -2.27 SD in the H group. Of the 126 subjects, 44, 40 and 40 subjects in the P, L and H groups, respectively, completed the 48 continuous wk of treatment. The changes in the mean height SD scores (mean growth rate) after 48 wk of treatment in the P, L and H groups were 0.07 SD, 0.03 SD, and 0.02 SD, respectively, and thus no significant differences was observed among the 3 groups. Also no significant changes in blood IGF-I levels at baseline or after 48 wk of treatment were observed among the 3 groups. This study revealed that in patients with GHD, an increase in endogenous GH secretion as a result of treatment with GHRP-2 does not promote growth. It is speculated that the area under the curve of serum GH concentration by GHRP-2 spray is too small to produce biological effects. In conclusion, it was demonstrated that growth cannot be promoted by a transient increase in endogenous GH secretion.

No MeSH data available.


Related in: MedlinePlus

Growth velocity before and during the 48 wk of treatment. Vertical bars indicate theSD. Numbers of subjects are shown in parentheses.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4219938&req=5

fig_003: Growth velocity before and during the 48 wk of treatment. Vertical bars indicate theSD. Numbers of subjects are shown in parentheses.

Mentions: Mean serum IGF-I concentrations before the GHRP-2 treatment and 48 wk after treatmentin three groups of GHRP-2 doses. Vertical bars indicate the SD. Numbers of subjectsare shown in parentheses.


Increased Secretion of Endogenous GH after Treatment with an Intranasal GH-releasing Peptide-2 Spray Does Not Promote Growth in Short Children with GH Deficiency.

Tanaka T, Hasegawa Y, Yokoya S, Nishi Y - Clin Pediatr Endocrinol (2014)

Growth velocity before and during the 48 wk of treatment. Vertical bars indicate theSD. Numbers of subjects are shown in parentheses.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4219938&req=5

fig_003: Growth velocity before and during the 48 wk of treatment. Vertical bars indicate theSD. Numbers of subjects are shown in parentheses.
Mentions: Mean serum IGF-I concentrations before the GHRP-2 treatment and 48 wk after treatmentin three groups of GHRP-2 doses. Vertical bars indicate the SD. Numbers of subjectsare shown in parentheses.

Bottom Line: Also no significant changes in blood IGF-I levels at baseline or after 48 wk of treatment were observed among the 3 groups.This study revealed that in patients with GHD, an increase in endogenous GH secretion as a result of treatment with GHRP-2 does not promote growth.In conclusion, it was demonstrated that growth cannot be promoted by a transient increase in endogenous GH secretion.

View Article: PubMed Central - PubMed

Affiliation: Tanaka Growth Clinic, Tokyo, Japan ; Department of Medical Specialties, National Center for Child Health and Development, Tokyo, Japan.

ABSTRACT
We investigated whether treatment with an intranasal GH-releasing peptide (GHRP)-2 spray, which acts as a potent GH secretagogue that stimulates endogenous GH secretion, promotes growth in patients with GH deficiency (GHD). This study involved 126 prepubertal short children (81 males, 45 females) with a height SD score of -2 SD or less, who had been diagnosed as having GHD based on GH stimulation tests, and in whom the serum GH concentrations increased up to 9 ng/ml after preliminary administration of an intranasal GHRP-2 spray. The subjects included in this study were divided into 3 groups by use of a double-blind method; that is 44 were placed into the placebo group (P group: 30 males, 14 females), 41 were placed into the GHRP-2 low dose group (L group: 25 males, 16 females), and 41 were placed into the GHRP-2 high dose group (H group: 26 males, 15 females). Those with a body wt of less than 20 kg were administered a placebo (P group), 50 μg of GHRP-2 (L group) or 100 μg of GHRP-2 (H group), and those with a body wt of 20 kg or more were administered a placebo (P group), 100 µg of GHRP-2 (L group) or 200 µg of GHRP-2 (H group) twice daily (morning and evening) for 48 continuous wk. Age and height SD scores at baseline were not significantly different among the three groups: 7.5 yr old and -2.26 SD in the P group, 7.3 yr old and -2.38 SD in the L group, and 7.5 yr old and -2.27 SD in the H group. Of the 126 subjects, 44, 40 and 40 subjects in the P, L and H groups, respectively, completed the 48 continuous wk of treatment. The changes in the mean height SD scores (mean growth rate) after 48 wk of treatment in the P, L and H groups were 0.07 SD, 0.03 SD, and 0.02 SD, respectively, and thus no significant differences was observed among the 3 groups. Also no significant changes in blood IGF-I levels at baseline or after 48 wk of treatment were observed among the 3 groups. This study revealed that in patients with GHD, an increase in endogenous GH secretion as a result of treatment with GHRP-2 does not promote growth. It is speculated that the area under the curve of serum GH concentration by GHRP-2 spray is too small to produce biological effects. In conclusion, it was demonstrated that growth cannot be promoted by a transient increase in endogenous GH secretion.

No MeSH data available.


Related in: MedlinePlus